



Policy to facilitate access to medicines and drug products

Effective: 20 September, 2024
Version: 1.0

SCOPE

The scope of this policy is to control and enhance Camurus commitment to make our medicines and drug products available to as many patients as possible in a sustainable manner. This policy directly addresses the material sustainability aspect of access and affordability of medicines that is part of Camurus focus area Patients as identified in the company's Sustainability Policy.

This policy sets out the framework for Camurus work to address access to medicines, and applies to Camurus R&D, commercial, medical affairs, and sustainability functions.

OVERVIEW

Camurus is committed to improving the lives of patients with severe and chronic diseases by developing and giving patients access to innovative medicines that can empower patients, supports caregivers, and creates value for society.

Access to medicines is a priority of the World Health Organization (WHO). The WHO bases the principles of its access to medicines strategy on four central components: 1) rational selection and use of drugs; 2) affordable prices, 3) sustainable financing, and 4) reliable health and supply systems ensuring, efficiency, accessibility, and quality (1). The WHO constitution establishes that a progressive realization of that standard requires that companies involved in the development, manufacturing, and distribution of medicines take a responsibility to work towards creating a sustainable supply of medicines that continuously enhances the access to medicines on a non-discriminatory basis. In accordance with this WHO constitution, Camurus adheres to the provision that the highest attainable standard of health is one of the fundamental rights of every human being, without distinction of ethnicity, religion, political belief, sexual orientation, economic or social condition.

The United Nation Guiding Principles for Business and Human Rights (UNGPRBHR) contain an extension that applies specifically to the pharmaceutical industry called the Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines (2). These guidelines outline expectations placed upon pharmaceutical companies regarding their approach to creating sustainable access to medicines. Camurus Access to Medicines policy is designed to follow, commit to, and adhere to these guidelines.

In a healthcare environment characterized by increasingly high demand for cost effectiveness data, there is a need to raise awareness and improve the understanding of how evidence- and value-based treatments can contribute to improving clinical outcomes, wider societal benefits and resource savings.

Camurus continuously works and collaborates with healthcare providers, payors, and other decision makers to develop and lead strategies to provide data, and sustainable business cases to meet the requisites of this policy. This work includes communicating significant and growing evidence of the products' efficacy, application [utilization] and value within different patient populations, alongside

launching different initiatives to reduce barriers for patients to receive qualified treatments for their disease.

ROLES AND RESPONSIBILITIES

Role	Responsibility and Obligations
Executive Management Team (EMT)	<ul style="list-style-type: none"> • Set the strategic direction and goals to govern significant access to medicines aspects and achieve enhanced performance in the area of access to medicines • Ensure, within respective area of responsibility, that work is conducted in accordance with this policy, the sustainability policy, and the overall corporate strategy • Ensure availability of adequate competence and allocation of required resources
Chief Commercial Officer (CCO)	<ul style="list-style-type: none"> • Steer and maintain this policy
Chief Financial Officer (CFO)	<ul style="list-style-type: none"> • Advise on financial and accounting implications of this policy
Chief Medical Officer (CMO)	<ul style="list-style-type: none"> • Advise on medical implications of this policy. • Develop and lead strategies to ensure that the evidence base around the company's products keeps growing.
Senior Vice President R&D	<ul style="list-style-type: none"> • Advise on R&D implications and opportunities created by this policy • Utilize policy to help shape and drive R&D pipeline • Establish and review pipeline for medicines that address unmet medical needs
Global Pricing Committee (GPC)	<ul style="list-style-type: none"> • Review, approve and authorize pricing of all medicines and drug products in accordance with this policy and SOP-0142 (3)
Director Sustainability	<ul style="list-style-type: none"> • Author of the policy and responsible for updating when necessary

POLICY

Camurus undertakes to formally recognize, respect and work in accordance with all internationally recognized human rights including the right to the highest attainable standard of health. It is with this recognition and respect in mind that Camurus makes a commitment, to, in a sustainable manner, enhance access to medicines for as many people in need as possible. The company's products are developed to provide value and benefit for both patients and society (4).

Camurus aligns with shared goal of society and the WHO to enhance healthcare affordability and accessibility for all. To achieve this, healthcare systems, including all stakeholders operating within them, must focus on prioritizing sustainability by delivering the most value to patients and society.

Value-based healthcare offers a pathway towards sustainable healthcare delivery. In value-based healthcare, all stakeholders are motivated to optimize patient outcomes and societal benefits. By placing patients at the core of our corporate strategy, Camurus creates innovative interventions that are intended to generate value to, and create the most potential for, improving the efficiency of the healthcare systems in which it operates.

Camurus contributes to this shift towards value-based healthcare by directing its research and development (R&D) towards addressing unmet medical needs and focusing on outcomes that truly matter. Camurus systematically incorporates access to medicines strategies into how it researches, develops, and distributes medicines globally. New drug candidates are carefully evaluated with a focus on five criteria: medical need; technology match; streamlined clinical trials; exclusivity and intellectual property (IP); and market potential. In addition to this process, Camurus will endeavor to demonstrate the value of its medicines to both patients, health economies and the wider society. The Global Pricing Committee (GPC) leads this evaluation and works to ensure that the value proposition of the medicine for all parties is fully recognized.

The principles upon which Camurus bases this commitment are three-fold:

1. **R&D to meet unmet medical needs:** Camurus will regularly and systematically assess its R&D project pipeline against unmet medical needs of severe and chronic diseases, and incorporate these needs, where appropriate, into the company's product development strategy.
2. **Accessibility:** Camurus will strive to agree prices for new medicines based on the value to patients, healthcare systems, and society that allows both access to patients and a sustainable business to ensure long-term viability. The company will work to make its medicines available to as many patients in need as possible by considering innovative and effective affordability pricing mechanisms that can assist broadening access in a sustainable way. The company's strategies will also strive to account for national gross domestic product, whilst maintaining the sustainability of its business. Camurus will endeavor to make its medicines available in both low income countries and low and medium income countries on a case-by-case basis at a sustainable price for both parties. Camurus also focuses on reducing barriers to access that are not purely financial, such as stigma and lack of education regarding disease and treatment alternatives.
3. **Reinforcing and empowering healthcare systems:** Camurus will continue to strive to lower the barriers to healthcare delivery and provision. Camurus will achieve this through continuous collaboration with governments, international healthcare organizations, and non-governmental organizations (NGOs), to support and improve the quality of patient care in areas where it can have the greatest impact. This work includes educating and supporting both patients and healthcare workers to better understand and manage the diseases that they live and work with.

In addition to these core principles, Camurus is committed to:

- Complying with applicable national and international access to medicine and drug product related legislations
- Continuously improving access performance by setting patient goals that create societal benefits.
- Providing relevant employees, and healthcare professionals with education in the area of patient access where appropriate
- Taking effective measures to ensure that all information bearing upon the safety, efficacy, and possible side effects of a medicine are accurately described and communicated in line with regulatory requirements, so that informed decisions about possible use of a medicine can be taken.

- Providing disease state education and awareness campaigns to enhance the general public's knowledge of diseases and disease management and encourage patients to seek treatment for their symptoms, while not in any way promoting the use of any specific medicine
- Recognizing the importance of targeted product donations in the form of disaster relief assistance or as emergency support in the event of humanitarian crises
- Collaborating with third parties such as healthcare providers, governments, and relevant non-governmental healthcare organizations to adopt access to medicines and value-based healthcare initiatives that lower barriers to the sustainable provision of the company's medicines.

For more information about Camurus' commitments on access to medicines, value-based healthcare systems, and for examples and case studies, please see Camurus' annual reports.

POLICY COMPLIANCE

This policy applies to the EMT, and employees of the commercial, R&D, medical, sustainability and finance departments at Camurus. Each line manager is responsible for ensuring that her/his/their team is acting in accordance with this policy.

Employees are encouraged and expected to report incidents of non-compliance with this policy to Camurus' Compliance Officer or by using Camurus' whistleblower platform, which is available on the intranet as well as the Camurus corporate website. Camurus has a non-retaliation rule and will ensure that there are no adverse work-related consequences for any employee who, in good faith, reports violations of this policy.